LAB vs AZTA vs NTRA vs PACB vs SEER

For growth investors, Natera, Inc.

(NTRA) is the stronger pick with 35. 9% revenue growth year-over-year, versus -51. 1% for Standard BioTools Inc. (LAB). Analysts rate Standard BioTools Inc. (LAB) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Natera, Inc.

(NTRA) delivered a total return of +115. 9%, compared to -95. 1% for Seer, Inc. (SEER). Over 10 years, the gap is even starker: NTRA returned +20. 9% versus SEER's -96. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Seer, Inc.

(SEER) is the lower-risk stock at 0. 84β versus Pacific Biosciences of California, Inc. 's 2. 43β — meaning PACB is approximately 189% more volatile than SEER relative to the S&P 500. On balance sheet safety, Azenta, Inc. (AZTA) carries a lower debt/equity ratio of 6% versus 142% for Pacific Biosciences of California, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Natera, Inc.

(NTRA) is pulling ahead at 35. 9% versus -51. 1% for Standard BioTools Inc. (LAB). On earnings-per-share growth, the picture is similar: Standard BioTools Inc. grew EPS 61. 5% year-over-year, compared to -70. 1% for Pacific Biosciences of California, Inc.. Over a 3-year CAGR, NTRA leads at 41. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Natera, Inc.

(NTRA) is the more profitable company, earning -9. 0% net margin versus -620. 9% for Seer, Inc. — meaning it keeps -9. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AZTA leads at -1. 9% versus -717. 7% for SEER. At the gross margin level — before operating expenses — NTRA leads at 64. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for LAB: 225.

0% to $3. 25.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Seer, Inc.

(SEER) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 84)). Standard BioTools Inc. (LAB) carries a higher beta of 2. 01 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SEER: -96. 7%, LAB: -89. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: LAB is a small-cap quality compounder stock; AZTA is a small-cap quality compounder stock; NTRA is a mid-cap high-growth stock; PACB is a small-cap quality compounder stock; SEER is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.